CL2011002923A1 - Cepa de mycoplasma hyopneumoniae; composicion de vacuna que la comprende; metodo de preparacion; y su uso para prevenir una enfermedad causada por mycoplasma hyopneumoniae en un animal porcino. - Google Patents

Cepa de mycoplasma hyopneumoniae; composicion de vacuna que la comprende; metodo de preparacion; y su uso para prevenir una enfermedad causada por mycoplasma hyopneumoniae en un animal porcino.

Info

Publication number
CL2011002923A1
CL2011002923A1 CL2011002923A CL2011002923A CL2011002923A1 CL 2011002923 A1 CL2011002923 A1 CL 2011002923A1 CL 2011002923 A CL2011002923 A CL 2011002923A CL 2011002923 A CL2011002923 A CL 2011002923A CL 2011002923 A1 CL2011002923 A1 CL 2011002923A1
Authority
CL
Chile
Prior art keywords
mycoplasma hyopneumoniae
strain
preparation
prevent
vaccine composition
Prior art date
Application number
CL2011002923A
Other languages
English (en)
Inventor
Rima Youil
El-Osta Youssef Abs
Glenn Browning
Phillip Markham
Original Assignee
Univ Melbourne
Bioproperties Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009902255A external-priority patent/AU2009902255A0/en
Application filed by Univ Melbourne, Bioproperties Pty Ltd filed Critical Univ Melbourne
Publication of CL2011002923A1 publication Critical patent/CL2011002923A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA CEPA DE VACUNA DE MYCOPLASMA HYOPNEUMONIAE, LA CUAL COMPRENDE UNA MUTACIÓN EN CUANDO MENOS UNO DE LOS GENES EN LISTADOS O CÓMO FUERON DEPOSITADOS EN EL NATIONAL MEASUREMENTS INSTITUTE (AUSTRALIA), BAJO EL NÚMERO DE ACCESO NM04/41259, CUYA CEPA ES SENSIBLE A LA TEMPERATURA Y ESTÁ ATENUADA, A UNA VACUNA QUE COMPRENDE ESTA CEPA, Y A LOS MÉTODOS Y USOS DE LA MISMA.<br />  
CL2011002923A 2009-05-19 2011-11-18 Cepa de mycoplasma hyopneumoniae; composicion de vacuna que la comprende; metodo de preparacion; y su uso para prevenir una enfermedad causada por mycoplasma hyopneumoniae en un animal porcino. CL2011002923A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2009902255A AU2009902255A0 (en) 2009-05-19 Bacterial strain, vaccine and uses thereof

Publications (1)

Publication Number Publication Date
CL2011002923A1 true CL2011002923A1 (es) 2012-08-31

Family

ID=43125658

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002923A CL2011002923A1 (es) 2009-05-19 2011-11-18 Cepa de mycoplasma hyopneumoniae; composicion de vacuna que la comprende; metodo de preparacion; y su uso para prevenir una enfermedad causada por mycoplasma hyopneumoniae en un animal porcino.

Country Status (17)

Country Link
US (1) US8524252B2 (es)
EP (1) EP2453913B1 (es)
JP (1) JP5744852B2 (es)
KR (1) KR101734590B1 (es)
CN (1) CN102458462B (es)
AU (1) AU2010251761B2 (es)
BR (1) BRPI1010679B1 (es)
CA (1) CA2762587C (es)
CL (1) CL2011002923A1 (es)
DK (1) DK2453913T3 (es)
EA (1) EA021102B1 (es)
ES (1) ES2579935T3 (es)
MX (1) MX2011012362A (es)
NZ (1) NZ596722A (es)
PE (1) PE20120909A1 (es)
WO (1) WO2010132932A1 (es)
ZA (1) ZA201109185B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201291175A1 (ru) 2010-05-19 2013-06-28 Байопропертис Пти Лтд. Способы, относящиеся к аттенуированной микоплазме
EP2684959A1 (en) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
CN104685057B (zh) * 2012-07-10 2019-04-16 海博莱科学有限公司 用于转化猪肺炎支原体的载体，转化的猪肺炎支原体菌株及其用途
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
EA038206B1 (ru) 2012-12-28 2021-07-23 Бёрингер Ингельхайм Ветмедика Гмбх Иммуногенная композиция, содержащая антигены микоплазм
EP2913947B1 (en) * 2014-02-27 2019-11-27 ADVA Optical Networking SE Passive optical network and optical line terminal
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
US10071149B2 (en) 2016-05-03 2018-09-11 Brigham Young University Temperature sensitive multivalent Bordetella avium vaccines
CN113278575B (zh) * 2021-07-13 2021-12-31 南华大学 一种肺炎支原体减毒突变株及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
CN1100871C (zh) * 1999-06-25 2003-02-05 江苏省农业科学院畜牧兽医研究所 猪肺炎支原体克隆致弱株
US6673567B2 (en) * 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2644195A1 (en) * 2006-03-03 2007-09-13 Merial Limited Mycoplasma hyopneumoniae vaccine
JP5869221B2 (ja) * 2007-11-06 2016-02-24 ゾエティス・ダブリュー・エルエルシー アジュバント添加マイコプラズマ・ハイオニューモニエ非病原性生ワクチン
SI2475384T1 (sl) * 2009-09-10 2016-12-30 Merial, Inc. Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin
US9324223B2 (en) 2012-06-08 2016-04-26 3M Innovative Properties Company Electronic monitoring home unit and installation methods

Also Published As

Publication number Publication date
JP5744852B2 (ja) 2015-07-08
BRPI1010679A2 (pt) 2017-07-18
EA021102B1 (ru) 2015-04-30
PE20120909A1 (es) 2012-08-19
AU2010251761B2 (en) 2014-10-09
EP2453913A1 (en) 2012-05-23
EP2453913A4 (en) 2013-10-30
CA2762587A1 (en) 2010-11-25
KR101734590B1 (ko) 2017-05-11
MX2011012362A (es) 2012-04-19
CN102458462A (zh) 2012-05-16
AU2010251761A1 (en) 2011-12-22
US20120135040A1 (en) 2012-05-31
CN102458462B (zh) 2014-03-19
ZA201109185B (en) 2012-09-26
WO2010132932A1 (en) 2010-11-25
EP2453913B1 (en) 2016-06-22
JP2012527218A (ja) 2012-11-08
ES2579935T3 (es) 2016-08-17
US8524252B2 (en) 2013-09-03
DK2453913T3 (en) 2016-07-25
EA201190311A1 (ru) 2012-06-29
NZ596722A (en) 2013-08-30
KR20120016282A (ko) 2012-02-23
CA2762587C (en) 2017-11-28
BRPI1010679B1 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
CL2011002923A1 (es) Cepa de mycoplasma hyopneumoniae; composicion de vacuna que la comprende; metodo de preparacion; y su uso para prevenir una enfermedad causada por mycoplasma hyopneumoniae en un animal porcino.
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112013003862A2 (pt) composição removedora de ferrugem
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CR20120264A (es) Compuestos
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
AR099592A1 (es) Control ajustable de composiciones de cemento de puzolana y cal
UY30820A1 (es) Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
UY33238A (es) &#34;Compuestos en calidad de antagonistas de bradiquinina-b1&#34;
BR112018013011A2 (pt) composições de alimento para animais de estimação
CL2013001589A1 (es) Uso de una emulsion que comprende 0,08% en peso o menos de aceite esencial antimicrobiano, goma acacia y agua para proporcionar un efecto antimicrobiano en una composicion acuosa; proceso para mejorar el efecto antimicrobiano de un aceite esencial antimicrobiano; y composicion acuosa que comprende una emulsion antimicrobiana.
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
CY1118835T1 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
IT1397734B1 (it) Uso di estratti naturali di tannini e non tannini atti a migliorare la fertilita&#39; del suolo e determinare un effetto starter sulle colture, e fitocomplesso di tannini e di non tannini per tale uso.
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
ES2528913T1 (es) Composiciones de transferencia de calor y métodos
CO6260091A2 (es) Derivados de iminopiridina y su uso
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
CL2013003093A1 (es) Composiciones que comprende cation de polihidroxioxoaluminio detectable por rmn; metodo de fabricacion de los mismos; y su uso.
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides